Immunotherapy and cancer – making the past prologue
Susan F. Slovin · Clinical Investigation · 2012
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2012
Abstract
The goals of all novel therapies include improvement in overall survival, quality of life and disease control. We are fortunate to finally have two therapies that have demonstrated survival benefit in Phase III clinical trials – one, ipilimumab, a monoclonal antibody against CTLA-4, a checkpoint inhibitor, and the other, Sipuleucel-T, an autologous-based cellular therapy. Ipilimumab is the second drug that has been approved for melanoma within the last year, suggesting that there are multiple ways to achieve antitumor responses.
Sipuleucel-T is the first immunotherapy approved for asymptomatic, castration-resistant prostate cancer, and while Sipuleucel-T lengthened survival modestly, there was no improvement in time to progression and no responders. While Sipuleucel-T has been well-tolerated, ipilimumab has been associated with autoimmune-related events. As single agents, these drugs have shown benefit; however, maximizing durability remains a challenge. This article provides support for our continued eff...
Open the resolved locator · 10.4155/cli.12.82
Metadata licence: OpenAlex metadata (CC0)